Q120 US Joint Fluid Replacement Market: Riding Out the COVID-19 Storm

Written by Freddy Buntoum | 6/8/20 9:35 PM

Coming through Q120 bruised and expecting much harder punches before the calm, companies ride the COVID-19 storm

According to SmartTRAK Financial Dashboard, Q120 revenue for the US Joint Fluid Replacement market was down -2.8%, which is within the range predicted by market leaders and physicians in SmartTRAK’s Impact of COVID-19 on the US Joint Fluid Replacement and Regenerative Medicine Injectable Markets for Knee OA*. Albeit revenue is down for Q120, the stay-at-home orders across US states triggered by the rapid spread of COVID-19 were not implemented until mid-March, which helped to mitigate what could have been much bigger losses.

Among the many topics covered in the comprehensive Q120 US Joint Fluid Replacement Market Recap* are:

Complete Market Overview with Company Revenues and Shares
Single-Injection: Leading the HA Market
2-Injection: Fidia's Hymovis Revenue Growth
3-Injection: Downward Trend Continues
5-Injection: Negative Growth
Notable Achievement in Q120

Although demand, adoption rate, and awareness continue to fuel growth for the lowest HA treatment options, with single-injection and 2-injection YoY positive growth, this was not enough to pull the entire US Joint Fluid Replacement market into positive territory for Q120. Additionally, not only did the COVID-19 crisis impact total revenue at the tail-end of Q120, some HA players are indicating that suppliers of extended-release corticosteroid, as well as Platelet-Rich Plasma (PRP) injectable products are making a more aggressive competitive push into the HA market...

Read the entire Q120 US Joint Fluid Replacement Market Recap including news, data, charts, company revenues and analysis*...

*The entire article can only be viewed by SmartTRAK subscribers to this module. For more information on how to receive a demo and subscribe, please click the button below.

Learn More

View full post